Supplementary Materials from Chemotherapy-Induced Macrophage Infiltration into Tumors Enhances Nanographene-Based Photodynamic Therapy

The Supplementary Materials file contains the following: 1) Supplementary Methods; 2) Supplementary Fig. S1: structure and characterizations of GO(HPPH)-PEG; 3) Supplementary Fig. S2: in vitro stability of GO(HPPH)-PEG; 4) Supplementary Fig. S3: singlet oxygen sensor green assay for free HPPH and GO(HPPH)-PEG; 5) Supplementary Fig. S4: in vivo NIRF imaging of free HPPH and GO(HPPH)-PEG; 6) Supplementary Fig. S5: in vivo PDT efficiency of free HPPH and GO(HPPH)-PEG; 7) Supplementary Fig. S6: in vivo NIRF imaging of 4T1 tumor-bearing mice after intratumoral injection of IRDye800-labeled F4/80+ macrophages; 8) Supplementary Fig. S7: ex vivo microdistribution analysis of CM-DiI-labeled F4/80+ macrophages in tumor tissues; 9) Supplementary Fig. S8: ex vivo NIRF imaging of GO(HPPH)-PEG; 10) Supplementary Fig. S9: flow cytometric analysis of integrin β6 for 4T1 tumor cells; 11) Supplementary Fig. S10: in vivo NIRF imaging of GO(HPPH)-PEG in control and CTX-treated 4T1 tumor-bearing mice; 12) Supplementary Fig. S11: immunofluorescence analysis of integrin β6 and F4/80 in 4T1 tumor tissues; 13) Supplementary Fig. S12: the synthetic scheme of IRDye800-αF4/80-Fab and 99mTc-αF4/80-Fab; 14) Supplementary Fig. S13: SDS-PAGE and in vitro NIRF imaging of IRDye800-αF4/80-Fab and αF4/80-Fab; 15) Supplementary Fig. S14: in vitro macrophage-specific binding of IRDye800-αF4/80-Fab; 16) Supplementary Fig. S15: in vivo specific targeting of IRDye800-αF4/80-Fab; 17) Supplementary Fig. S16: in vitro macrophage-specific binding of 99mTc-αF4/80-Fab.